Drug Trial Radar · NCT07013487
A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12,000
Planned (sponsor's estimate)
Start
Jun 11, 2025
Primary completion
Sep 6, 2031
Study completion Sep 6, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.
Conditions
- Healthy
Interventions
V181Biological
Participants will receive a single 0.5 mL SC dose of V181 on Day 1.
PlaceboBiological
Participants will receive a single 0.5 mL SC dose of placebo on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing a Medically Attended Adverse Event (MAAE)Time frame: Up to approximately 6 months postvaccination
- Percentage of Participants Experiencing a Serious Adverse Event (SAE)Time frame: Up to approximately 5 years postvaccination
- Reactogenicity and Immunogenicity Subset: Percentage of Participants Experiencing Solicited Injection-site AEsTime frame: Up to approximately 5 days postvaccination
- Reactogenicity and Immunogenicity Subset: Percentage of Participants Experiencing Solicited Systemic AEsTime frame: Up to approximately 28 days postvaccination
- Percentage of Participants Experiencing Symptomatic (Requiring Fever on at Least 2 of 3 Consecutive Days) VCD of Any Severity, Due to Any of the 4 Dengue Serotypes, Regardless of Dengue Serostatus at BaselineTime frame: Up to approximately 3 years postvaccination
Locations
41 sites in 7 countries. Site status is shown where the registry gives one.
Jatinegara Primary Health Center ( Site 0102)
East Jakarta, Jakarta Special Capital Region, Indonesia
Cipayung Primary Health Center ( Site 0105)
East Jakarta, Jakarta Special Capital Region, Indonesia
Dr Cipto Mangunkusumo Hospital-Pediatrics ( Site 0101)
Jakarta, Jakarta Special Capital Region, Indonesia
Kelapa Gading Primary Health Center ( Site 0104)
North Jakarta, Jakarta Special Capital Region, Indonesia
Pasar Minggu Primary Health Center ( Site 0103)
South Jakarta, Jakarta Special Capital Region, Indonesia
Hospital Tunku Azizah-Paediatric ( Site 0022)
Kuala Lumpur, Malaysia
Hospital Pakar Kanak - Kanak UKM (HPKK) ( Site 0024)
Cheras, Kuala Lumpur, Malaysia
University Malaya Medical Centre-Department of Paediatrics ( Site 0025)
Lembah Pantai, Kuala Lumpur, Malaysia
Hospital Sibu ( Site 0021)
Sibu, Sarawak, Malaysia
Hospital Ampang ( Site 0028)
Ampang, Selangor, Malaysia
Hospital Al-Sultan Abdullah - Universiti Teknologi MARA ( Site 0029)
Bandar Puncak Alam, Selangor, Malaysia
Sunway Medical Centre ( Site 0027)
Petaling Jaya, Selangor, Malaysia
Health Index Multispecialty And Lying-In Clinic ( Site 0042)
Bacoor, Cavite, Philippines
Chong Hua Hospital ( Site 0051)
Cebu City, Cebu, Philippines
Norzel Medical and Diagnostic Clinic Foundation Corp ( Site 0044)
Cebu City, Central Visayas (Region VII), Philippines
West Visayas State University Medical Center ( Site 0045)
Iloilo City, Iloilo, Philippines
Philippine General Hospital ( Site 0041)
Manila, National Capital Region, Philippines
University of the Philippines Manila ( Site 0047)
Metro Manila, National Capital Region, Philippines
Clinical Research Investigator Group ( Site 0110)
Bayamón, Puerto Rico
San Juan Bautista School of Medicine - Clinical Research Unit ( Site 0114)
Caguas, Puerto Rico
Ponce Medical School Foundation Inc./CAIMED Center ( Site 0112)
Ponce, Puerto Rico
Latin Clinical Trial Center ( Site 0113)
San Juan, Puerto Rico
Wellness clinical Research Vega Baja ( Site 0116)
Vega Baja, Puerto Rico
National University Hospital-Paediatrics ( Site 0001)
Singapore, Central Singapore, Singapore
KK Women's and Children's Hospital ( Site 0002)
Singapore, Central Singapore, Singapore
Tan Tock Seng Hospital ( Site 0003)
Singapore, Central Singapore, Singapore
Chulalongkorn University-Pediatrics ( Site 0063)
Bangkok, Bangkok, Thailand
Faculty of Tropical Medicine, Mahidol University ( Site 0062)
Bangkok, Bangkok, Thailand
Queen Sirikit National Institute of Child Health-Pediatric Infectious Disease ( Site 0071)
Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital-Pediatric Infectious Diseases ( Site 0065)
Bangkok, Bangkok, Thailand
Faculty of Tropical Medicine, Mahidol University - Vaccine Trial Centre ( Site 0067)
Ratchathewi, Bangkok, Thailand
Kamphaeng Phet-AFRIMS Virology Research Unit KAVRU ( Site 0070)
Muang, Changwat Kamphaeng Phet, Thailand
Faculty of Medicine - Khon Kaen University-Pediatrics ( Site 0064)
Amphoe Mueang, Changwat Khon Kaen, Thailand
Thammasat University Hospital-Department of Pediatrics ( Site 0068)
Khong Luang, Changwat Pathum Thani, Thailand
Songklanagarind hospital-Department of Pediatrics ( Site 0061)
Hat Yai, Changwat Songkhla, Thailand
Maharaj Nakorn Chiang Mai Hospital ( Site 0066)
Muang, Chiang Mai, Thailand
Quang Nam Hospital for Women and Children ( Site 0094)
Da Nang, Vietnam
Dong Thap General Hospital ( Site 0092)
Dong Thập, Vietnam
Pasteur Institute in Ho Chi Minh city ( Site 0089)
Ho Chi Minh City, Vietnam
Kien Giang Women's and Children hospital ( Site 0091)
Rach Gia, An Giang, Vietnam
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.